Visual Acuity: Clinical Trials

2 trials for Visual Acuity, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Terminated 2

Follow Visual Acuity: new trials by email Literature Review of Visual Acuity trials Research Report on Visual Acuity

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Treatment of Refractory Diabetic Macular Edema With Infliximab
infliximab, placebo - Diabetic Macular Edema, Visual Acuity
Phase 3TerminatedUniversity of Athens122007-07-012009-02-20
EAGLE - Multicenter Study of the European Assessment Group for Lysis in the Eye
Intravenous injection of heparin, Intravenous injection of acetazolamide, Local intra-arterial fibrinolysis - Retinal Artery Occlusion, Fibrinolysis
Phase 3TerminatedUniversity Hospital Freiburg842002-09-012008-03-18

Narrower conditions

Diabetes Mellitus (1)  ·  Diabetic Retinopathy (1)  ·  Macular Degeneration (1)  ·  Macular Edema (1)  ·  Retinal Artery Occlusion (1)  ·  Stroke (1)  ·  Vision Disorders (1)

Broader conditions

Cardiovascular Diseases (2)  ·  Eye Diseases (2)  ·  Nervous System Diseases (2)  ·  Retinal Diseases (2)  ·  Vascular Diseases (2)  ·  Arterial Occlusive Diseases (1)  ·  Brain Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Cerebrovascular Disorders (1)  ·  Diabetes Complications (1)  ·  Diabetic Angiopathies (1)  ·  Endocrine System Diseases (1)  ·  Glucose Metabolism Disorders (1)  ·  Metabolic Diseases (1)  ·  Neurologic Manifestations (1)

Interventions

Aspirin (1)  ·  Infliximab (1)

Sponsors

University Hospital Freiburg (1)  ·  University of Athens (1)

Countries

Austria (1)  ·  Germany (1)  ·  Greece (1)  ·  Switzerland (1)

Top investigators

Martin Schumacher, Professor (1)  ·  Petros Sfikakis, MD (1)

Results publications

PMID 20413522, PMID 26349479